Nucleus Basalis Of Meynert is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
The [Nucleus Basalis of Meynert[/brain-regions/[nucleus-basalis-of-meynert[/brain-regions/[nucleus-basalis-of-meynert[/brain-regions/[nucleus-basalis-of-meynert[/brain-regions/[nucleus-basalis-of-meynert--TEMP--/brain-regions)--FIX-- (NBM) is a collection of large cholinergic projection [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the basal forebrain that provides the primary cholinergic innervation to the entire neocortex. Degeneration of NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- is one of the earliest and most consistent pathological hallmarks of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, directly contributing to the cortical cholinergic deficit that underlies attention, learning, and memory impairments 1). The discovery of NBM neuronal loss in AD by Peter Whitehouse and colleagues in 1982 gave rise to the cholinergic hypothesis of AD and led directly to the development of [cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX-- as the first approved AD [treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/[treatments[/treatments.
The NBM is now being investigated as a target for [deep brain stimulation[/therapeutics/[deep-brain-stimulation[/therapeutics/[deep-brain-stimulation[/therapeutics/[deep-brain-stimulation[/therapeutics/[deep-brain-stimulation--TEMP--/therapeutics)--FIX-- (DBS) to enhance cortical cholinergic function in AD patients, with several [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials reporting preliminary safety and feasibility data.
¶ Location and Organization
The NBM is located in the substantia innominata of the basal forebrain:
- Corresponds to the Ch4 cell group in Mesulam's cholinergic nomenclature system
- Spans from the anterior commissure posteriorly to the level of the [mammillary bodies[/brain-regions/[mammillary-bodies[/brain-regions/[mammillary-bodies[/brain-regions/[mammillary-bodies[/brain-regions/[mammillary-bodies--TEMP--/brain-regions)--FIX--
- Situated ventral and medial to the [globus pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus[/brain-regions/[globus-pallidus--TEMP--/brain-regions)--FIX--
- Extends anteriorly into the diagonal band of Broca (Ch2/Ch3 groups)
- Receives afferent input from the [amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--, [hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus--TEMP--/brain-regions)--FIX--, [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX-- monoaminergic nuclei, and [prefrontal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
The NBM contains distinct neuronal populations:
- Large cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (30-60 um diameter): The predominant cell type (~90%); use [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- as their primary neurotransmitter
- GABAergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--: Local interneurons and a subset of projection [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Glutamatergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--: Recently identified subset with cortical projections
- Neuropeptide-expressing [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--: Subpopulations co-expressing galanin, substance P, or neuropeptide Y
NBM cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- project topographically to specific cortical regions:
| NBM Subdivision |
Cortical Target |
Function |
| Anteromedial Ch4 |
Cingulate [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, medial frontal |
Attention, motivation |
| Anterolateral Ch4 |
Frontal operculum, anterior insular |
Language, visceral sensation |
| Intermediate Ch4 |
Lateral frontal, parietal, temporal |
Executive function, spatial processing |
| Posterior Ch4 |
Superior temporal, [entorhinal cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex--TEMP--/brain-regions)--FIX-- |
Auditory, memory |
| Ch4i (intermediate) |
[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- (via entorhinal) |
Memory encoding |
This topographic organization means that selective NBM neuronal loss produces region-specific cortical cholinergic deficits, potentially explaining the heterogeneity of cognitive symptoms in AD.
The NBM-cortical cholinergic system modulates cortical function rather than directly driving it:
- Attention: Phasic acetylcholine release enhances signal detection and stimulus processing; the NBM is essential for sustained attention
- Learning and memory: [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- facilitates encoding of new information in [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and neocortex; enables synaptic plasticity ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--
- Cortical activation: Tonic NBM activity maintains cortical arousal and wakefulness
- Sensory processing: Sharpens sensory [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- receptive fields through cholinergic modulation
- [Neuroplasticity[/mechanisms/[neuroplasticity[/mechanisms/[neuroplasticity[/mechanisms/[neuroplasticity[/mechanisms/[neuroplasticity--TEMP--/mechanisms)--FIX--: [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX-- release during learning opens critical period-like plasticity windows in adult [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- Tonic release: Sustained low-level [ACh] maintains cortical arousal state
- Phasic bursts: Brief high-amplitude [ACh] release during attention-demanding tasks
- Volume transmission: [ACh] diffuses through cortical tissue affecting populations of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (not purely synaptic)
- Muscarinic receptors (M1-M5): Slow, metabotropic signaling; M1 predominates in [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- Nicotinic receptors (alpha4beta2, alpha7): Fast ionotropic signaling; important for attention
NBM cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- depend on neurotrophic support:
- Nerve growth factor (NGF): The primary survival factor for basal forebrain cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--; retrogradely transported from cortical targets
- Brain-derived neurotrophic factor (BDNF): Supports cholinergic neuron survival and function
- TrkA receptor: High-affinity NGF receptor expressed by NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--; loss correlates with cholinergic degeneration in AD
- p75NTR receptor: Low-affinity neurotrophin receptor; may promote [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX-- when NGF is depleted
NBM neuronal loss is among the most severe and consistent pathological findings in AD:
- Neuronal loss: 50-90% reduction in NBM cholinergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in moderate-to-severe AD 1)
- Early vulnerability: NBM degeneration begins in preclinical AD stages (Braak stage I-II)
- Selective vulnerability: Large cholinergic projection [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are preferentially affected, while smaller interneurons are relatively spared
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--(/proteins/tau pathology: NBM neurons accumulate neurofibrillary tangles at very early Braak stages (among the first [brain regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/brain-regions affected by tau]
- Aβ] pathology: [Amyloid] plaques are found in the NBM but neuronal loss may precede plaque formation
- Correlation with symptoms: Degree of NBM loss correlates with severity of cortical cholinergic deficit and cognitive impairment
Several factors make NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- uniquely susceptible to AD pathology:
- Long-range projections: Extensive axonal arbors create high metabolic demands and vulnerability to transport dysfunction
- NGF deprivation: Impaired retrograde NGF transport from [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- to NBM cell bodies leads to trophic factor withdrawal
- Pro-NGF accumulation: In AD, mature NGF decreases while pro-NGF (which promotes apoptosis via p75NTR) increases
- Tau burden: NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are among the earliest to develop tau pathology; NFTs disrupt axonal transport
- Oxidative stress: High cholinergic metabolic activity generates oxidative species
- [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- toxicity: NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- express receptors (alpha7 nicotinic, p75NTR) that bind [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- with high affinity
- Cholinergic-specific vulnerability: ChAT expression and acetylcholine synthesis decline before neuronal loss
| Consequence |
Mechanism |
Clinical Manifestation |
| Cortical [ACh] deficit |
Loss of cholinergic innervation |
Memory impairment, inattention |
| Reduced cortical activation |
Loss of tonic cholinergic tone |
Drowsiness, fluctuating consciousness |
| Impaired plasticity |
Loss of [ACh]-dependent synaptic modification |
Learning deficits |
| [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- |
Loss of cholinergic anti-inflammatory signaling |
Microglial activation |
| Accelerated [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- deposition |
Loss of [ACh]-mediated alpha |
Increased amyloidogenic processing |
¶ Lewy Body Dementia
- [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- (DLB) shows NBM degeneration comparable to or exceeding AD
- Explains the prominent attentional fluctuations characteristic of DLB
- [alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX-- Lewy bodies in NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Greater cholinergic deficit in DLB may explain better response to cholinesterase inhibitors
- [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- dementia (PDD) involves significant NBM neuronal loss
- Cholinergic deficit contributes to PD-associated cognitive impairment
- [Rivastigmine[/treatments/[rivastigmine[/treatments/[rivastigmine[/treatments/[rivastigmine[/treatments/[rivastigmine--TEMP--/treatments)--FIX-- (cholinesterase inhibitor) is approved for PDD
- [PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX-- involves moderate NBM neuronal loss
- Contributes to executive dysfunction and attention deficits
- Less severe than in AD or DLB
The first-line pharmacotherapy for AD targets the cholinergic deficit caused by NBM degeneration:
- [Donepezil[/entities/[donepezil[/entities/[donepezil[/entities/[donepezil[/entities/[donepezil--TEMP--/entities)--FIX--, [galantamine[/treatments/[galantamine[/treatments/[galantamine[/treatments/[galantamine[/treatments/[galantamine--TEMP--/treatments)--FIX--, rivastigmine]: Increase synaptic acetylcholine by inhibiting acetylcholinesterase
- Provide modest symptomatic benefit (2-4 points on ADAS-Cog)
- Do not prevent ongoing NBM neuronal loss
- Effectiveness limited by continued cholinergic denervation
NBM-DBS is an emerging investigational approach:
- Rationale: Low-frequency electrical stimulation of NBM may enhance residual cholinergic neuron firing and cortical [ACh] release
- Phase 1 trial in severe AD (2024): A study by Xu et al. explored NBM-DBS feasibility in [late[/diseases/[late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX---stage severe AD patients, demonstrating safety over 1-year follow-up with no serious DBS-related adverse effects 3)
- Preclinical findings (2024-2025): Burst stimulation patterns outperform tonic stimulation in rat dementia models; optimal stimulation duration appears to be ~5 hours/day rather than continuous
- Challenges: Variable clinical efficacy; optimal stimulation parameters undefined; patient selection criteria unclear; invasive neurosurgical procedure
- Current status: Small proof-of-concept trials; inconclusive clinical efficacy data; larger randomized trials needed
- NGF [gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--: AAV-delivered NGF to NBM region showed some evidence of cholinergic neuron rescue in Phase 1 trials but limited clinical efficacy
- Encapsulated cell biodelivery: Implantable capsules releasing NGF near the NBM
- Small-molecule TrkA agonists: Oral compounds mimicking NGF signaling
- p75NTR modulators: Blocking pro-NGF-mediated apoptosis of NBM [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- [Cholinergic Neurons (Basal Forebrain) – Related cell type[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain--TEMP--/cell-types)--FIX--
- [Alzheimer's Disease – Primary disease association[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Neurotransmitter Systems – Acetylcholine signaling[/entities/[neurotransmitter-systems[/entities/[neurotransmitter-systems[/entities/[neurotransmitter-systems[/entities/[neurotransmitter-systems--TEMP--/entities)--FIX--
- [Nerve Growth Factor (NGF) – Therapeutic target[/entities/[nerve-growth-factor[/entities/[nerve-growth-factor[/entities/[nerve-growth-factor[/entities/[nerve-growth-factor--TEMP--/entities)--FIX--
- [Cell Types Index[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/cell-types
The study of Nucleus Basalis Of Meynert has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Whitehouse PJ, et al. Alzheimer's Disease and senile dementia: loss of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the basal forebrain. Science. 1982;215[1]
- [Mesulam MM, et al. Cholinergic innervation of [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis [2]
- [Xu J, et al. Deep brain stimulation of the nucleus basalis of Meynert in severe Alzheimer's Disease. J Alzheimers Dis. 2024;102[3]
- [Grothe M, et al. Atrophy of the [cholinergic basal forebrain[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain[/cell-types/[cholinergic-basal-forebrain--TEMP--/cell-types)--FIX--/cell-types/cholinergic-basal-forebrain] over the adult age range and in early stages of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Biol Psychiatry. 2012;71[4]
- [Mufson EJ, et al. Cholinergic system during the progression of Alzheimer's Disease: therapeutic implications. Expert Rev Neurother. 2008;8[5]
- [Kuhn J, et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia. Mol Psychiatry. 2015;20[6]
- [Tuszynski MH, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer's Disease. Nat Med. 2005;11[7]
- [Mesulam M. The cholinergic lesion of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: pivotal factor or side show? Learn Mem. 2004;11[8]
- [Hampel H, et al. The cholinergic system in the pathophysiology and treatment of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Brain. 2018;141[9]
- [Nandi A, et al. Electrical stimulation of the nucleus basalis of Meynert: a systematic review of preclinical and clinical data. Sci Rep. 2021;11[10]
- [Cuello AC, et al. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's Disease. Curr Alzheimer Res. 2007;4[11]